- Home
- RCEL vs BTMD Comparison
RCEL vs BTMD Comparison
Compare RCEL & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- BTMD
- Stock Information
- Founded
- RCEL N/A
- BTMD 2012
- Country
- RCEL United States
- BTMD United States
- Employees
- RCEL N/A
- BTMD N/A
- Industry
- RCEL Medical/Dental Instruments
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- RCEL Health Care
- BTMD Health Care
- Exchange
- RCEL Nasdaq
- BTMD Nasdaq
- Market Cap
- RCEL 107.8M
- BTMD 90.6M
- IPO Year
- RCEL N/A
- BTMD N/A
- Fundamental
- Price
- RCEL $3.42
- BTMD $2.84
- Analyst Decision
- RCEL Buy
- BTMD Buy
- Analyst Count
- RCEL 5
- BTMD 2
- Target Price
- RCEL $11.80
- BTMD $6.00
- AVG Volume (30 Days)
- RCEL 260.2K
- BTMD 102.3K
- Earning Date
- RCEL 11-06-2025
- BTMD 11-05-2025
- Dividend Yield
- RCEL N/A
- BTMD N/A
- EPS Growth
- RCEL N/A
- BTMD 271.49
- EPS
- RCEL N/A
- BTMD 0.78
- Revenue
- RCEL $74,884,000.00
- BTMD $195,645,000.00
- Revenue This Year
- RCEL $20.40
- BTMD N/A
- Revenue Next Year
- RCEL $32.94
- BTMD $4.85
- P/E Ratio
- RCEL N/A
- BTMD $3.67
- Revenue Growth
- RCEL 38.32
- BTMD 1.34
- 52 Week Low
- RCEL $3.37
- BTMD $2.65
- 52 Week High
- RCEL $14.16
- BTMD $6.98
- Technical
- Relative Strength Index (RSI)
- RCEL 28.06
- BTMD 45.59
- Support Level
- RCEL $3.88
- BTMD $2.78
- Resistance Level
- RCEL $3.91
- BTMD $2.90
- Average True Range (ATR)
- RCEL 0.23
- BTMD 0.15
- MACD
- RCEL -0.05
- BTMD 0.01
- Stochastic Oscillator
- RCEL 0.00
- BTMD 30.75
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.